Table 4.
Observed change from baseline to week 24 by region in the placebo group
| Eastern Europe/Turkey (n = 259a) | Western Europe/Israel (n = 254b) | USA/Canada (n = 145c) | South America/Mexico (n = 119d) | Asia (n = 53) | Australia/South Africa (n = 32e) | p value for equality of variances | |
|---|---|---|---|---|---|---|---|
| ADAS-Cog, mean (SD) | 0.32 (6.59) | 1.40 (6.24)SA | 0.55 (5.72) | −0.71 (5.32)WE | 0.17 (5.28) | 1.56 (5.89) | 0.29 |
| ADCS-CGIC, mean (SD)f | 4.18 (0.95)WE | 4.51 (1.03)EE,SA | 4.39 (0.90)SA | 3.98 (1.35)WE,US | 4.30 (0.85) | 4.41 (1.04) | < 0.0001 |
| ADCS-ADL23, mean (SD) | −0.59 (7.59)WE | −3.21 (7.68)EE | −1.78 (8.45) | −1.44 (7.07) | −1.77 (5.71) | −2.76 (8.03) | 0.60 |
| NPI, mean (SD) | −1.03 (9.95) | 0.45 (9.39) | −0.46 (10.53) | −1.39 (11.42) | −0.13 (6.44) | −1.73 (10.32) | 0.66 |
| MMSE, mean (SD) | 0.10 (3.08)WE,US | −0.79 (2.80)EE | −0.77 (3.00)EE | −0.34 (2.34) | −0.58 (2.73) | −1.22 (3.03) | 0.42 |
ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive subscale, ADCS-ADL23 Alzheimer’s Disease Cooperative Study—Activities of Daily Living, 23-item version, ADCS-CGIC Alzheimer’s Disease Cooperative Study—Clinical Global Impression of Change, MMSE Mini–Mental State Examination, NPI Neuropsychiatric Inventory, SD standard deviation
Pairwise comparisons: EEp < 0.05 versus Eastern Europe/Turkey; WEp < 0.05 versus Western Europe/Israel; USp < 0.05 versus USA/Canada; SAp < 0.05 versus South America/Mexico
aExcept MMSE, n = 260
bExcept ADCS-CGIC, n = 250
cExcept ADCS-CGIC, n = 143
dExcept ADCS-CGIC, n = 117
eExcept ADCS-ADL23 and NPI, n = 33
fMean (SD) score at week 24 is presented for ADCS-CGIC. The scale is itself a measure of change from baseline, meaning that change scores are not applicable. Scores > 4 indicate worsening